Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: Results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

Annals of the Rheumatic Diseases

Volumn 75, Issue 2, 2016, Pages 323-331

  Isenberg, D A ^a,h   Petri, M ^b   Kalunian, K ^c   Tanaka, Y ^d   Urowitz, M B ^e   Hoffman, R W ^f   Morgan Cox, M ^f   Iikuni, N ^f   Silk, M ^f   Wallace, D J ^g  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^e UNIVERSITY OF TORONTO   (Canada)

^f ELI LILLY AND COMPANY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PLACEBO; TABALUMAB; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HERPES ZOSTER; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MILIARY TUBERCULOSIS; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THRUSH; TREATMENT RESPONSE; ADOLESCENT; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; BLACK PERSON; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; ETHNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BIOMARKERS; COMPLEMENT C3; COMPLEMENT C4; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84954302328     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207653     Document Type: Article

References (26)

1. Lisnevskaia L, Murphy G, Isenberg DA. Systemic lupus erythematosus. Lancet 2014;384:1878-88.
2. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007;369:587-96.
3. Murphy G, Lisnevskaia L, Isenberg DA. Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Lancet 2013;382:809-18.
4. Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014;73:183-90.
5. Stohl W. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets 2014;18:473-89.
6. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747-56.
7. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009;119:1066-73.
8. Darce JR, Arendt BK, Wu X, et al. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007;179:7272-86.
9. Stohl W, Metyas S, Tan S, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003;48:3475-86.
10. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58;2453-9.
11. Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
12. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.
13. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
14. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999;8:685-91.
15. Wolfe F. Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. J Rheumatol 2004;31:1896-902.
16. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999;85:1186-96.
17. Merrill JT, van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:332-40
18. Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 2015;74: 2006-15.
19. Genovese MC, Fleischmann RM, Greenwald M, et al. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis 2013;72:1461-8.
20. Genovese MC, Lee E, Satterwhite J, et al. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2013;72:1453-60.
21. Greenwald M, Szczepanski L, Kennedy A, et al. A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis. Arthritis Res Ther 2014;16:415.
22. Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum 2013;65:2672-9.
23. FDA approves Benlysta to treat lupus: First new lupus drug approved in 56 years. FDA. 9 Mar 2011. http://www.fda.gov/newsevents/newsroom/pressAnnouncements/ucm246489.htm (accessed 13 Feb 2015).
24. Belimumab. Approved indication: systemic lupus erythematosus. Aust Prescr 2013;36:139-42. http://www.australianprescriber.com/magazine/36/4/139/42/new-drugs/1028/belimumab-for-systemic-lupus-erythematosus (accessed 3 Mar 2015).
25. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
26. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.